Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 801–900 of 1,000
A Comparative Analysis of the Molecular Interaction Techniques for In Silico Drug Design
Sarkar, A., & Sen, S. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09830-6 · Cited by 13
Inferring Drug-Related Diseases Based on Convolutional Neural Network and Gated Recurrent Unit
Xuan, P., Zhao, L., Zhang, T., Ye, Y., & Zhang, Y. (2019) · Molecules · doi:10.3390/molecules24152712 · Cited by 11
“[16] proposed a drug side effect similarity to determine whether two drugs are involved in the same target.”
BackgroundRepositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis
Prakash, A. V., Park, J. W., Seong, J.-W., & Kang, T. J. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.001 · Cited by 10
“Currently, in silico methods such as data mining, bioinformatics, and novel screening platforms are being used in drug repositioning projects for the identification and screening of potential repositioning candidates (Li et al., 2006; Yildirim et al., 2007; Campillos et al., 2008; Yamanishi et al., 2008; Kieser et al.…”
BackgroundMethodHengphasatporn, K., Plaimas, K., Suratanee, A., Wongsriphisant, P., Yang, J., Shigeta, Y., Chavasiri, W., Boonyasuppayakorn, S., & Rungrotmongkol, T. (2020) · Molecules · doi:10.3390/molecules25081883 · Cited by 10
Drug‐target‐ADR Network and Possible Implications of Structural Variants in Adverse Events
Dafniet, B., Cerisier, N., Audouze, K., & Taboureau, O. (2020) · Molecular Informatics · doi:10.1002/minf.202000116 · Cited by 10
Dimensionality reduction based multi-kernel framework for drug-target interaction prediction
Mahmud, S., Chen, W., Jahan, H., Liu, Y., & Hasan, S. M. M. (2021) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2021.104270 · Cited by 10
Machine Learning and Deep Learning Strategies in Drug Repositioning
Wang, F., Ding, Y., Lei, X., Liao, B., & Wu, F. (2021) · Current Bioinformatics · doi:10.2174/1574893616666211119093100 · Cited by 10
Li, G., Zhang, P., Sun, W., Ren, C., & Wang, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab557 · Cited by 10
Direct and Selective Electrocarboxylation of Styrene Oxides with CO2 for Accessing β‐Hydroxy Acids
Zhang, K., Ren, B., Liu, X., Wang, L., Zhang, M., Ren, W., Lu, X., & Zhang, W. (2022) · Angewandte Chemie · doi:10.1002/ange.202207660 · Cited by 10
Deep Reinforcement Learning for Medicine Recommendation
Symeonidis, P., Chairistanidis, S., & Zanker, M. (2022) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe55377.2022.00026 · Cited by 16
“Previous work [1], [2] in medical research has already tried to exploit drug-target or drug-side effect correlations to find similarities between drugs for the task of drug-target or drug-side effect prediction, respectively.”
BackgroundCAT-Site: Predicting Protein Binding Sites Using a Convolutional Neural Network
Petrovski, Ž. H., Hribar-Lee, B., & Bosnić, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010119 · Cited by 10
“On the other hand, in certain cases, this so-called offtarget binding has been found to have multiple beneficent effects as well [6].”
BackgroundIntegrating Clinical Phenotype and Gene Expression Data to Prioritize Novel Drug Uses
Paik, H., Chen, B. D., Sirota, M., Hadley, D., & Butte, A. J. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12108 · Cited by 11
“Based on the shared side effects between drugs, Campillos et al.(30) also presented a prediction of similar drugs (1,017 pairs of drugs consisting of 424 drugs).”
BackgroundResultInfluentialA simple mathematical approach to the analysis of polypharmacology and polyspecificity data
Maggiora, G. M., & Gokhale, V. M. (2017) · F1000Research · doi:10.12688/f1000research.11517.1 · Cited by 11
Cava, C., & Castiglioni, I. (2019) · Gene · doi:10.1016/j.gene.2019.02.064 · Cited by 10
Rymbai, E., Sugumar, D., Saravanan, J., & Divakar, S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110156 · Cited by 11
Antiviral drug repurposing: different approaches and the case of antifungal drugs
Tuci, S., Mercorelli, B., & Loregian, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108903 · Cited by 10
MicroRNA targets: potential candidates for indirect regulation by drugs
Arora, A. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000111 · Cited by 9
Zhijing Powder Treats Hypertension by Regulating PI3k/AKT Signaling Pathway
Wang, Y., Zhang, P., Li, H., Chen, P., Zhang, X., Wang, B., & Zhang, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12777 · Cited by 9
Preclinical side effect prediction through pathway engineering of protein interaction network models
Alidoost, M., & Wilson, J. L. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13150 · Cited by 9
“A study by Campillos et al. 14 illustrated that when drug side effect profiles are similar, this can serve as a predictive factor for common drug targets.”
BackgroundPredicting Drug Promiscuity Using Spherical Harmonic Surface Shape-Based Similarity Comparisons
Pérez‐Nueno, V. I. (2011) · The Open Conference Proceedings Journal · doi:10.2174/2210289201102010113 · Cited by 9
“These range from the well-known docking of compounds into protein structures to the use of machine learning methods [11, 12], sequence comparison [13] side-effect similarity [6], and fingerprint/pharmacophore comparison methods [14, 15].”
BackgroundMethodDrug Side Effect Profiles as Molecular Descriptors for Predictive Modeling of Target Bioactivity
Baker, N., Fourches, D., & Tropsha, A. (2015) · Molecular Informatics · doi:10.1002/minf.201400134 · Cited by 11
A Tool to Utilize Adverse Effect Profiles to Identify Brain-Active Medications for Repurposing
McCoy, T. H., & Perlis, R. H. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu078 · Cited by 9
“This work relies on previous reports (Campillos et al., 2008; Tatonetti et al., 2012) that described the methodology for deriving adverse effect profiles from pre- and postmarketing data, then utilized similarities between pairs to suggest common targets.”
BackgroundMethodGreenside, P., Hillenmeyer, M. E., & Kundaje, A. B. (2017) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813235533_0003 · Cited by 9
“Other classes of methods [Campillos et al. 2008] follow a “guilt by association” principle by trying to determine similarity of an uncharacterized compound to other compounds with known targets.”
MethodNozaka, A., Nishiwaki, A., Nagashima, Y., Endo, S., Kuroki, M., Nakajima, M., Narukawa, M., Kamisuki, S., Arazoe, T., Taguchi, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41039-x · Cited by 10
Repurposing Drugs to Treat Heart and Brain Illness
Cantrell, M. S., Soto-Avellaneda, A., Wall, J. D., Ajeti, A. D., Morrison, B. E., Warner, L., & McDougal, O. M. (2021) · Pharmaceuticals · doi:10.3390/ph14060573 · Cited by 9
“Using this strategy, prediction of the likelihood that two drugs had the same target based on their side effects was demonstrated [12].”
BackgroundComputational drug repurposing for viral infectious diseases: a case study on monkeypox
Saha, S., Chatterjee, P., Nasipuri, M., Basu, S., & Chakraborti, T. (2024) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad058 · Cited by 9
Zhu, W., Qiu, X., Xu, X., & Lu, C. (2010) · Science China Chemistry · doi:10.1007/s11426-010-4082-0 · Cited by 9
Pharmacovigilance, Drug Repositioning, and Virtual Screening
Flower, D. R. (2013) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000e103 · Cited by 11
“[25] used recorded side-effect similarities to identify drugs with the same target.”
BackgroundMethodChen, L., Wang, Q., Zhang, L., Tai, J., Wang, H., Wan, L., Li, X., He, W., & Li, X. (2011) · Molecular BioSystems · doi:10.1039/c0mb00249f · Cited by 9
Mannil, D., Vogt, I., Prinz, J., & Campillos, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku948 · Cited by 10
“Side effect similarity has been employed to identify new drug targets (1) and functional relations between disease genes have been found among diseases that share symptoms (2,3).”
BackgroundMethodInfluentialSelf-citationQuantitative knowledge-based analysis in compound safety assessment
Bureeva, S. V., & Nikolsky, Y. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.553191 · Cited by 9
“Schematic representation of knowledge-base approaches applied by A [68]; B [6] and C [25].”
BackgroundMethodInfluentialCai, X., Chen, Y., Gao, Z., & Xu, R. (2016) · PubMed Central · Cited by 11
TRPV4-Mediated Anti-nociceptive Effect of Suberanilohydroxamic Acid on Mechanical Pain
Choi, G., Yang, T., Yoo, S., Choi, S.-I., Lim, J. Y., Cho, P. S., & Hwang, S. W. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1093-x · Cited by 9
Dissez, G., Ceddia, G., Pinoli, P., Ceri, S., & Masseroli, M. (2019) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3307339.3342154 · Cited by 10
“Campillos et al. [1], instead, used a side effect similarity approach for drug repositioning.”
MethodAzad, A., Fatima, S., Capraro, A., Waters, S. A., & Vafaee, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100325 · Cited by 9
Machine learning approaches for predicting the onset time of the adverse drug events in oncology
Timilsina, M., Tandan, M., & Nováček, V. (2022) · Machine Learning with Applications · doi:10.1016/j.mlwa.2022.100367 · Cited by 14
“The study by Dandala, Joopudi, Tsou, Liang, and Suryanarayanan (2020) showed that deep learning models trained in drug-centric concepts and relations have a competitive advantage over other state-of-the-art models for predicting ADR.”
InfluentialLarge-scale Analysis of Drug Combinations by Integrating Multiple Heterogeneous Information Networks
Chen, H., Iyengar, S. K., & Li, J. (2019) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3307339.3342142 · Cited by 10
“Previous studies have found that weak drug-drug similarities and disease-disease similarities provide little information for the network inferences [8, 46].”
BackgroundBiases of Drug–Target Interaction Network Data
van Laarhoven, T., & Marchiori, E. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-09192-1_3 · Cited by 9
“It would also be interesting to consider other interaction datasets, such as the drug–target, enzyme–motabolite and protein–ligand datasets from [17, 3, 9, 15, 18].”
BackgroundZhang, S., Zhang, R., Zheng, L., Liu, Y., Fan, Q., Liu, Y., Ning, X., Zhang, Y., Chen, Y., & Liu, H. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11247-x · Cited by 10
“Clinical observations analyzed using text mining methods can also provide links between diseases and drug repositioning [143, 144].”
Xu, D. D., Zhou, D., Bum‐Erdene, K., Bailey, B. J., Sishtla, K. L., Liu, S., Wan, J., Aryal, U. K., Lee, J. A., Wells, C. D., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00078 · Cited by 8
DSNet: Predicting drug-side effect frequencies via Dual-Graph Ensemble and Similarity Learning
Long, Q., Zhao, N., & Liu, H. (2025) · Knowledge-Based Systems · doi:10.1016/j.knosys.2025.113537 · Cited by 10
Remez, N., García-Serna, R., Vidal, D., & Mestres, J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00470 · Cited by 9
Compound Collection Preparation for Virtual Screening
Bologa, C., & Oprea, T. I. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-965-5_7 · Cited by 11
Cavalla, D., Oerton, E., & Bender, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12283-8 · Cited by 9
Chakraborti, S., Ramakrishnan, G., & Srinivasan, N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_3 · Cited by 10
Predicting Disease-related Associations by Heterogeneous Network Embedding
Xiong, Y., Ruan, L., Guo, M., Tang, C., Kong, X., Zhu, Y., & Wang, W. W. (2018) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2018.8621538 · Cited by 8
Centrality analysis in a drug network and its application to drug repositioning
Keng, Y. Y., Kwa, K. H., & Ratnavelu, K. (2020) · Applied Mathematics and Computation · doi:10.1016/j.amc.2020.125870 · Cited by 10
A drug repositioning algorithm based on a deep autoencoder and adaptive fusion
Chen, P., Bao, T., Yu, X., & Liu, Z. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04406-y · Cited by 8
“Verifying whether two drugs can act on the same target through drug side effect data was proposed in the literature [19].”
BackgroundChakkittukandiyil, A., Chakraborty, S., Kothandan, R., Rymbai, E., Muthu, S., Vasu, S., Sajini, D. V., Sugumar, D., Mohammad, Z. B., Saravanan, J., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2258968 · Cited by 10
“Additionally, molecules with comparable side effects may have similar downstream effects because of their proximity in the biochemical network (Campillos et al., 2008).”
Budak, B., Tükel, E. Y., Turanlı, B., & Kiraz, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05821-w · Cited by 8
“The L1000CDS2 [57] comprises a repository of 30,000 drug expression profiles derived from data sourced from the Library of Integrated Network-based Cellular Signatures (LINCS)-L1000 dataset [58].”
MethodDrugs, non-drugs, and disease category specificity: organ effects by ligand pharmacology1
García‐Sosa, A. T., & Maran, U. (2013) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2013.773373 · Cited by 8
“In addition, compounds with similar side-effects have been linked to similar activities against a variety of biological targets [9].”
BackgroundAn Optimized Drug Similarity Framework for Side-effect Prediction
Zheng, Y., Ghosh, S., & Li, J. (2017) · Computing in cardiology · doi:10.22489/cinc.2017.128-068 · Cited by 8
“Two previous studies demonstrated that side-effects and target proteins have strong relations [2] [3].”
BackgroundJain, P., Jain, S. K., & Jain, M. (2020) · Current Molecular Medicine · doi:10.2174/1566524020666200619125404 · Cited by 10
Structure‐based protein‐protein interaction networks and drug design
Naveed, H., & Han, J. J. (2013) · Quantitative Biology · doi:10.1007/s40484-013-0018-y · Cited by 8
“Successful repositioning of drugs for novel targets has been achieved not only using approved drugs [120] but also using late stage failures [121,122].”
BackgroundUsing a Human Drug Network for generating novel hypotheses about drugs
Rahmani, H., Blockeel, H., & Bender, A. (2016) · Intelligent Data Analysis · doi:10.3233/ida-150800 · Cited by 9
“Campillos et al. [39] predict new targets for established drugs looking for side-effects shared between two molecules.”
Design of a tripartite network for the prediction of drug targets
Kunimoto, R., & Bajorath, J. (2018) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-018-0098-x · Cited by 8
Drug-drug relationship based on target information: application to drug target identification
Park, K., & Kim, D. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-s2-s12 · Cited by 8
“calculated the target-sharing probabilities of drugs based on the similarity of side effects and chemical structure [21].”
BackgroundGlobalized bipartite local model for drug-target interaction prediction
Mei, J.-P., Kwoh, C.-K., Yang, P., Li, X., & Zheng, J. (2012) · doi:10.1145/2350176.2350178 · Cited by 7
Noor, A., & Assiri, A. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.03.068 · Cited by 8
Kaushik, A. C., Mehmood, A., Wei, D., Nawab, S., Sahi, S., & Kumar, A. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166037 · Cited by 8
Concept Modeling-based Drug Repositioning.
Patchala, J., & Jegga, A. G. (2015) · PubMed Central · Cited by 9
Mapping drug-target interaction networks
Tian, L., & Zhang, S. (2009) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2009.5335053 · Cited by 7
“This demonstrated the feasibility of using annotated information to infer molecular interactions and possible new use or off-target activities of the marketed drugs [ 13 ].”
BackgroundDing, P., Liang, C., Ouyang, W., Li, G., Xiao, Q., & Luo, J. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2951557 · Cited by 7
Approaches for network based drug discovery
Jayachandran, P., Ilango, S., Paital, B., Bhanja, S., & Nirmaladevi, R. (2021) · Frontiers in Bioscience-Scholar · doi:10.52586/s551 · Cited by 8
“Different types of similarity-based methods are available including 3D shape-based similarity [72], two-dimensional (2D) fingerprint-based similarity [ 73], and phenotypic based similarity [34] methods.”
MethodTangmanussukum, P., Kawichai, T., Suratanee, A., & Plaimas, K. (2022) · PeerJ Computer Science · doi:10.7717/peerj-cs.1124 · Cited by 7
“To predict DTIs, the existing similarity-based methods ( e.g. , Bleakley & Yamanishi, 2009 ; Campillos et al., 2008 ) mostly utilized the drug similarity only based on chemical structures and the target similarity only based on protein sequences.”
MethodRepurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
Wasim, R., Ansari, T. M., Siddiqui, M. H., Ahsan, F., Shamim, A., Singh, A. N., Shariq, M., Anwar, A., Siddiqui, A. R., & Parveen, S. (2023) · Hormone and Metabolic Research · doi:10.1055/a-1971-6965 · Cited by 7
“This technique was used to assess the likelihood that two medications had the same target based on their side effects [13].”
BackgroundMethodXie, D., Huang, Q., & Zhou, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087656 · Cited by 8
Mei, H., Feng, G., Zhu, J., Lin, S. M., Qiu, Y., Wang, Y., & Xia, T. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_33 · Cited by 9
ElGamacy, M., & Meervelt, L. V. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0091-5 · Cited by 8
“…in protein–protein interactions [1], disease underlying protein networks [2], protein binding pocket analysis [3], shared side-effects networks for drug target identification [4], protein–ligand phylogenetic analysis [5], cross-binding ligand networks [6], and even in network pharmacology [7].”
BackgroundSemantic Breakthrough in Drug Discovery
Chen, B., Wang, H., Ding, Y., & Wild, D. J. (2015) · Synthesis lectures on data, semantics and knowledge · doi:10.1007/978-3-031-79456-8 · Cited by 8
Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis
Muftuoglu, Y., & Mustata, G. I. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-92 · Cited by 7
“One major problem that drug developers face is that many drugs share similar targets, as evidenced by phenotypic side-effects similarities [28], or that a given drug may be capable of targeting more than one protein.”
BackgroundSun, Y., Narayan, V. A., & Wittenberg, G. M. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0090-9 · Cited by 8
“A recent strategy applied has focused on drug side effect profile similarities [20, 21], based on the notion than we may not know all of the biological effects of our known compounds, but similarities in mechanism within the human environment may be revealed by similarities in side effects.”
BackgroundIn Silico Drug Discovery and Design
Lill, M. A. (2013) · doi:10.4155/9781909453012 · Cited by 8
Huang, G., Li, J., & Zhao, C. (2018) · Molecules · doi:10.3390/molecules23040954 · Cited by 7
Noh, K., Yoo, S., & Lee, D. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2196-0 · Cited by 7
“In addition to the molecular similarity, we utilized target and related phenotype information to find similarities in binding proteins and overall phenotypic effects [16, 17].”
Learning Latent Patterns in Molecular Data for Explainable Drug Side Effects Prediction
Hu, P., You, Z., He, T., Li, S., Gu, S., & Chan, K. C. C. (2018) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2018.8621121 · Cited by 7
“To do so, several machine learning algorithms have been proposed to determine possible association between drug substructures and drug SEs [8-9].”
BackgroundLi, G., Xu, Y., Liu, G., Zheng, M., Zhang, X., Hang, Y., & Kang, J. (2020) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202000353 · Cited by 7
Recommending What Drug to Prescribe Next for Accurate and Explainable Medical Decisions
Symeonidis, P., Chairistanidis, S., & Zanker, M. (2021) · Proceedings - IEEE Symposium on Computer-Based Medical Systems · doi:10.1109/cbms52027.2021.00021 · Cited by 8
Jouffroy, M., Nguyen, T. M., Cordier≈, M., Blot, M., Roisnel, T., & Gramage‐Doria, R. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202201078 · Cited by 7
Nonlinear data fusion over Entity–Relation graphs for Drug–Target Interaction prediction
Mazzone, E., Moreau, Y., Fariselli, P., & Raimondi, D. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad348 · Cited by 7
Screening drug target proteins based on sequence information
Wang, J. T., Liu, W., Tang, H., & Xie, H. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.03.009 · Cited by 7
“, based on sideeffect similarity [9], based on ligands [10], or based on chemical structure and genomic sequence information [11]) and were aimed at integrating as much information as possible.”
MethodBietz, S., Inhester, T., Lauck, F., Sommer, K., von Behren, M. M., Fährrolfes, R., Flachsenberg, F., Meyder, A., Nittinger, E., Otto, T., et al. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.06.004 · Cited by 7
Halder, V., Oeljeklaus, J., Heilmann, G., Krahn, J. H., Liu, Y., Xiong, Y., Schlicht, M., Schillinger, J., Kracher, B., Ehrmann, M., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802647 · Cited by 7
Saad, A. I., Maghraby, F. A., & Omar, Y. M. K. (2019) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-14118-9_28 · Cited by 7
Ravanmehr, V., Blau, H., Cappelletti, L., Fontana, T., Carmody, L., Coleman, B., George, J., Reese, J., Joachimiak, M. P., Bocci, G., et al. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab113 · Cited by 7
“A broad range of computational methods have been developed, many of which construct networks (graphs) that comprise information about features such as mechanism of action, chemical and physiological processes, diseases, drugs, gene expression and others (27,35–37).”
BackgroundBiomarker and Drug Discovery for Gastroenterology Through Translational Bioinformatics
Dudley, J. T., & Butte, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.024 · Cited by 7
PROTEIN-CHEMICAL INTERACTION PREDICTION VIA KERNELIZED SPARSE LEARNING SVM
SHI, Y., Zhang, X., Liao, X., Lin, G., & Schuurmans, D. (2012) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814447973_0005 · Cited by 7
Machine learning for network data
van Laarhoven, T. M. (2014) · Radboud Repository (Radboud University) · Cited by 17
Innovative Mamba and graph transformer framework for superior protein-ligand affinity prediction
Han, K., Shi, C., Wang, Z., Liu, W., Li, Z., Wang, Z., Lei, L., Dai, R., Wang, M., Zhang, Z., et al. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111444 · Cited by 7
Drug targets prediction using chemical similarity
Galeano, D., & Paccanaro, A. (2016) · Latin American Computer Conference (CLEI) · doi:10.1109/clei.2016.7833353 · Cited by 7
Mining Biomedical Literature and Ontologies for Drug Repositioning Discovery
Wei, C., Chen, K.-A., & Chen, L.-C. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-06605-9_31 · Cited by 6
In-silico identification of 3,4-Diarylpyrazoles-based small molecules as potential Hsp90 inhibitors
Aboalroub, A. A., & Al-Najjar, B. O. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101757 · Cited by 8
Aboalroub, A. A. (2025) · Medinformatics · doi:10.47852/bonviewmedin52025019 · Cited by 9
Causal co-expression method with module analysis to screen drugs with specific target
Yu, S., Zheng, L., Li, Y., Li, C., Ma, C., Yu, Y., Li, X., & Hao, P. (2012) · Gene · doi:10.1016/j.gene.2012.11.051 · Cited by 6
Functional similarities of reaction sets in metabolic pathways
Ay, F., & Kahveci, T. (2010) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/1854776.1854795 · Cited by 6
“Identifying these similarities is of utmost importance for many applications such as drug target identification [4, 22], phylogeny reconstruction [8, 9], metabolic engineering [24] and biocommodity engineering [13].”
DenguePredict: An Integrated Drug Repositioning Approach towards Drug Discovery for Dengue.
Wang, Q., & Xu, R. (2015) · PubMed · Cited by 7
Mining Online Heterogeneous Healthcare Networks for Drug Repositioning
Zhao, M., & Yang, C. C. (2016) · IEEE International Conference on Healthcare Informatics (ICHI) · doi:10.1109/ichi.2016.18 · Cited by 7
“[26] used phenotypic side-effect similarities to infer whether two drugs share targets and to identify novel drug-target relationships.”
BackgroundSa, Z., Zhou, J., Zou, Y., Su, Z., & Gu, X. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.03.004 · Cited by 6
“Cross-reactivity arising from the structural and functional conservation of paralogs often results in undesirable side effects [37].”
BackgroundBioinformatic Approaches in the Understanding of Mechanism of Action ( MoA )
Trapotsi, M., Barrett, I. P., Engkvist, O., & Bender, A. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch11 · Cited by 6
Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors
Naveed, H., Reglin, C., Schubert, T. E. O., Gao, X., Arold, S. T., & Maitland, M. L. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.05.006 · Cited by 6
“In addition, novel targets for drugs have also been identified by comparing adverse effects [36] and by using genome-wide association studies [37].”
Background
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.